Stocks and Investing
Stocks and Investing
Tue, July 26, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Nierengarten Initiated (VOR) at Buy and Held Target at $18 on, Jul 26th, 2022
David Nierengarten of Wedbush, Initiated "Vor Biopharma Inc." (VOR) at Buy and Held Target at $18 on, Jul 26th, 2022.
David has made no other calls on VOR in the last 4 months.
There are 2 other peers that have a rating on VOR. Out of the 2 peers that are also analyzing VOR, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrea Tan of "Goldman Sachs" Maintained at Hold with Decreased Target to $4 on, Tuesday, May 24th, 2022
This is the rating of the analyst that currently disagrees with David
- Silvan Tuerkcan of "JMP Securities" Maintained at Buy with Decreased Target to $15 on, Friday, May 13th, 2022
Contributing Sources